KaloBios president and chief executive David Pritchard retires

11 January 2015

US pharma company KaloBios Pharmaceuticals (Nasdaq: KBIO) has announced its president and chief executive, David Pritchard, is to retire.

He has also resigned from the company’s board of directors. KaloBios’ current chief financial officer, Herb Cross, has been named as interim chief executive while a permanent replacement is sought.

Ted Love, chairman of the KaloBios board of directors, said: "On behalf of the board, I would like to express our thanks and appreciation to Dave for his years of service to KaloBios. His retirement comes at an opportune time as we transition out of the pulmonary space and focus our efforts entirely on oncology. The board is confident that Herb and the team will continue to advance the company's oncology programs while we commence an immediate search for a permanent CEO with strong oncology development expertise."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK